US20030203053A1 - Method and composition for improving sexual fitness - Google Patents
Method and composition for improving sexual fitness Download PDFInfo
- Publication number
- US20030203053A1 US20030203053A1 US10/407,221 US40722103A US2003203053A1 US 20030203053 A1 US20030203053 A1 US 20030203053A1 US 40722103 A US40722103 A US 40722103A US 2003203053 A1 US2003203053 A1 US 2003203053A1
- Authority
- US
- United States
- Prior art keywords
- composition
- ginseng
- dietary supplement
- arginine
- daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 238000000034 method Methods 0.000 title claims abstract description 62
- 230000001568 sexual effect Effects 0.000 title claims abstract description 36
- 235000008434 ginseng Nutrition 0.000 claims abstract description 64
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 62
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 60
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 53
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 36
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 35
- 229930064664 L-arginine Natural products 0.000 claims abstract description 35
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 34
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 30
- 241000208340 Araliaceae Species 0.000 claims abstract description 16
- 240000004371 Panax ginseng Species 0.000 claims description 55
- 239000000463 material Substances 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 27
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 20
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 17
- 229940088594 vitamin Drugs 0.000 claims description 17
- 229930003231 vitamin Natural products 0.000 claims description 17
- 235000013343 vitamin Nutrition 0.000 claims description 17
- 239000011782 vitamin Substances 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 15
- 230000004855 vascular circulation Effects 0.000 claims description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 13
- 239000011707 mineral Substances 0.000 claims description 13
- 235000010755 mineral Nutrition 0.000 claims description 13
- 230000036299 sexual function Effects 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 235000002789 Panax ginseng Nutrition 0.000 claims description 12
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 240000000143 Turnera diffusa Species 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 235000004952 turnera diffusa Nutrition 0.000 claims description 7
- 235000019156 vitamin B Nutrition 0.000 claims description 7
- 239000011720 vitamin B Substances 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 6
- 229940014144 folate Drugs 0.000 claims description 6
- 235000019157 thiamine Nutrition 0.000 claims description 6
- 239000011721 thiamine Substances 0.000 claims description 6
- 235000019155 vitamin A Nutrition 0.000 claims description 6
- 239000011719 vitamin A Substances 0.000 claims description 6
- 229940046001 vitamin b complex Drugs 0.000 claims description 6
- 230000035946 sexual desire Effects 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 4
- 230000035807 sensation Effects 0.000 claims description 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
- 229930182494 ginsenoside Natural products 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 12
- -1 for example Chemical compound 0.000 description 12
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- 239000000470 constituent Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 240000005373 Panax quinquefolius Species 0.000 description 8
- 229960000711 alprostadil Drugs 0.000 description 8
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 8
- 208000010228 Erectile Dysfunction Diseases 0.000 description 7
- 201000001881 impotence Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 241000218628 Ginkgo Species 0.000 description 6
- 235000011201 Ginkgo Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004648 relaxation of smooth muscle Effects 0.000 description 6
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000005226 corpus cavernosum Anatomy 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 229960002639 sildenafil citrate Drugs 0.000 description 5
- 235000007586 terpenes Nutrition 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000007897 gelcap Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 229940091258 selenium supplement Drugs 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007938 effervescent tablet Substances 0.000 description 3
- 230000009986 erectile function Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 229940105680 niacin 20 mg Drugs 0.000 description 3
- 229940023136 pantothenic acid 10 mg Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940089805 riboflavin 1.7 mg Drugs 0.000 description 3
- 230000035911 sexual health Effects 0.000 description 3
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 229940033282 vitamin b6 2 mg Drugs 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241001632410 Eleutherococcus senticosus Species 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 241000168720 Panax japonicus Species 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 238000010669 acid-base reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940107131 ginseng root Drugs 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- BUGBHKTXTAQXES-DBXDQKISSA-N selenium-70 Chemical compound [70Se] BUGBHKTXTAQXES-DBXDQKISSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012358 sourcing Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- NTHGIYFSMNNHSC-UHFFFAOYSA-N 3-methylbutyl nitrate Chemical compound CC(C)CCO[N+]([O-])=O NTHGIYFSMNNHSC-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 235000005769 Japanese ginseng Nutrition 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000003174 Panax japonicus Nutrition 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000062172 Turnera diffusa var. aphrodisiaca Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- VRYMTAVOXVTQEF-UHFFFAOYSA-N acetic acid [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] ester Chemical compound CC(C)C1=CC(OC(C)=O)=C(C)C=C1OCCN(C)C VRYMTAVOXVTQEF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940107628 american ginseng root Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- XRKMNJXYOFSTBE-UHFFFAOYSA-N disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+4].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] XRKMNJXYOFSTBE-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960004819 isoxsuprine Drugs 0.000 description 1
- 229940045792 korean ginseng root Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960003509 moxisylyte Drugs 0.000 description 1
- 229960001132 naftidrofuryl Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960003056 phentolamine mesylate Drugs 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention relates to the maintenance of a state of wellness in which sexual health is improved.
- the invention provides methods and compositions for maintaining a state of wellness in an animal by providing a dietary supplement comprising L-arginine, in combination with ginseng and optionally ginkgo biloba and/or additional nutritional supplements.
- the invention provides a unique blend of components that, in combination, synergistically bestow sexual wellness upon an animal when taken regularly as a dietary supplement alone, or in combination with a pharmaceutical composition which facilitates smooth muscle relaxation and vascular dilatation.
- One aspect of the invention is a composition for improving sexual fitness in an animal.
- the composition comprises (a) a metabolic precursor to nitric oxide. (b) a material for increasing nitric oxide synthase activity, and optionally (c) a material to promote vascular circulation, particularly microvascular circulation. Additional dietary supplements such as vitamins and minerals can also be included.
- Another aspect of the invention is a method for improving sexual function in an animal.
- the method comprises administering the composition described above.
- a third aspect of the invention is a method of treating sexual dysfunction in a male or female, e.g., erectile dysfunction in the male.
- the method comprises administering the composition described above.
- Yet another aspect of the invention is a method for preparing a composition useful for improving sexual fitness.
- the process comprises combining the components of the composition described above, preferably into unit dosage forms.
- a fifth aspect of the invention is an article of manufacture comprising the composition described above in combination with labeling that the composition is to be taken for sexual fitness.
- compositions and methods of the invention provide a dietary supplement useful for maintaining a state of wellness in an animal, preferably a laboratory animal or domesticated animal, even more preferably a human, whether male or female.
- composition and method of the invention are particularly useful for improving sexual fitness in both males and females.
- the composition and method are particularly useful for people who want to remain sexually active as they grow older.
- the composition of the invention comprises two, and preferably three, components: (a) a metabolic precursor to nitric oxide. (b) a material for increasing nitric oxide synthase activity, and optionally (c) a material to promote vascular circulation, particularly microvascular circulation.
- the composition is a dietary supplement that is delivered over time to achieve the desired results.
- a preferred dietary supplement of the invention comprises a combination of arginine, ginseng, and optionally ginkgo biloba, which is useful for improving blood flow and circulation. Improved blood flow is important for maintaining good sexual health.
- the compositions and methods of the invention improve sexual wellness without any undesirable side effects such as headache, nausea, gastric upset, chest pain, dizziness, vision disturbance, or change in blood pressure.
- the main component of the composition of this invention is a metabolic precursor to nitric oxide (NO), such as, for example, organic nitrates and nitrites and other compounds that are capable of conversion to nitric oxide. Many of such precursors are also called nitrovasodilators. Examples of organic nitrates include isoamyl nitrate, nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate and pentaerythritol.
- the precursor to NO is arginine.
- Arginine is an essential amino acid having the chemical name 2-amino-5-guanidinovaleric acid.
- the physiologically active form which is designated as the “L” form.
- the compound is readily available from various sources in the commercial market place such as from Sigma Chemical Company or Aldrich Chemical Company in a pharmaceutical grade. It generally is available as a powder that generally is associated with two moles of water and forms monoclinic plates.
- the L-arginine in the composition is free of other amino acids, peptides and proteins that would interfere with the uptake of L-arginine into the animal's system.
- the second component present in the composition is a material that increases nitric oxide synthase (NOS) activity.
- NOS nitric oxide synthase
- a preferred material is ginseng.
- Ginseng is material extracted from the root of a plant that is a member of the ginseng family (Araliaceae), genus Panax. Ginseng plants grow in Asia and North America. P. ginseng grows in Northern China (Chinese ginseng) and Korea (Korean ginseng). The material extracted from the root is referred to as white ginseng or red ginseng. The former is dried P.
- ginseng root while the latter is P. ginseng root steamed in caramel.
- American ginseng P. quinquefolium
- Other relatives include Japanese ginseng ( P. japonicum ), San-Chi ginseng ( P. notoginseng ), Himalayan ginseng ( P. pseudoginseng, ssp. himalaicus var argustifolius ) and Siberian ginseng ( Eleutherococcus senticosus ).
- the ginseng component in the composition is usually standardized ginseng obtained from plants originating from one or more geographical areas and comprises, in total, about 1% to about 50% ginsenosides, preferably about 10% to about 35% ginsenosides, more preferably about 15% to about 20% ginsenosides, most preferably about 17.5% ginsenosides.
- the ginseng component comprises American ginseng and Korean ginseng.
- the American ginseng comprises about 1% to about 50% ginsenosides, preferably about 1% to about 10% ginsenosides, more preferably about 5% ginsenosides.
- the Korean ginseng comprises about 1% to about 50% ginsenosides, preferably about 10% to about 40% ginsenosides, more preferably about 30% ginsenosides.
- the ginseng component in a liquid or tonic is usually one or more extracts of ginseng from various geographical areas having a ratio of herb to solvent when extracted of about 1:2 to about 1:10, preferably about 1:5.
- ginseng are available on the commercial market and are available from various sources, such as, for example, East Earth Herb and Natural Sourcing Solutions, Inc.
- the types and relative abundance of the chemical constituents of ginseng depend on the species, the part of the plant, the place of origin, the method of cultivation, and the technique of extraction used to obtain the ginseng.
- Different types of ginseng may have slightly different constituent profiles, but the type of ginseng used in this composition will be the material extracted from Panax ginseng or Panax quinquefolius.
- a mixture of American ginseng and Korean ginseng is employed.
- ginseng extracted from the roots of the various plants is quite similar among the different species used. Generally the ginseng will contain typical ginsenosides. A further discussion of the constituents of the various types of ginseng may be found in the American Chemical Society publication entitled “Folk Medicine: The Art and the Science,” edited by Richard P. Steiner, University of Utah (1986).
- the composition of this invention also comprises a material that promotes vascular circulation in the person receiving the composition.
- This material may be a pharmaceutical or a dietary supplement or herb.
- Some materials that promote vascular circulation are known as vasodilators, e.g., hydralazine, minoxidil, sodium nitroprusside, diazoxide, phentolamine mesylate, phentolamine hydrochloride, phenoxybenzamine, yohimbine, nitroglycerine, thymoxamine, imipramine, isoxsuprine, naftidrofuryl, tolazoline, papaverine, and calcium channel blockers that act as vasodilators, such as nifedipine, nicardipine, nimodipine, verapamil and diltiazem.
- Ginkgo biloba is extracted from the leaves of the ginkgo biloba tree. The leaves are harvested in late summer when the leaves have the highest level of active compounds. The extract is semipurified to remove undesirable compounds which do not contribute to the desired health benefits.
- the material can be highly concentrated and standardized to a known and consistent level of the active principals known as ginkgolides. Ginkgo biloba is readily available from the various sources throughout the herbal medicine industry, such as, for example, East Earth Herb and Natural Sourcing Solutions, Inc.
- the ginkgo component in the composition as a solid is usually standardized ginkgo and comprises about 1% to about 50% flavone glycosides, preferably about 15% to about 30% flavone glycosides, more preferably about 24% flavone glycosides, and about 1% to about 20% terpene lactones, preferably about 5% to about 10% terpene lactones, more preferably about 6% terpene lactones.
- the ginkgo component in a liquid or tonic is usually an extract having a ratio of herb to solvent when extracted of about 1:2 to about 1:5, preferably about 1:2.
- a dietary supplement composition comprising the combination of L-arginine, ginseng, and ginkgo biloba is administered to a subject orally as a capsule, tablet, powder or as an aqueous composition. If administered as a capsule, tablet, or powder, an amount of each of the three constituents is mixed in accordance with standard pharmaceutical practice to form a unit dosage that can be swallowed by taking water with the unit dosage. (See, for example, “Remington, The Science and Practice of Pharmacy,” Nineteenth Edition, Mack Publishing co. for a discussion of the preparation of tablets and capsules/chapters 91-93). In general, the size of the tablet or capsule will be less than about a gram to maximize the ease of swallowing.
- a dietary supplement also may contain antioxidant vitamins, vitamin-B-complex, and certain minerals. These additional constituents may be present in an amount up to about 100% of the daily values for each constituent for a male or female.
- “daily values” is meant the Reference Daily Intake (RDI) as defined in 21 CFR ⁇ 101.9(c)(8)(iv).
- Antioxidant vitamins include vitamins A (preferably as palmitate), C (preferably as ascorbic acid) and E (preferably as dl ⁇ tocopherol acetate).
- Vitamin-B complex includes thiamin (preferably as the mononitrate), riboflavin, niacin (preferably is niacinamide), vitamin B-6 (preferably as pyroxidine HCl), folate (preferable as folic acid), vitamin B-12 (preferably as cyanocobalamin), biotin, and pantothenic acid (preferably as calcium pantothenate).
- Minerals include zinc (preferably as zinc gluconate), calcium (preferably as calcium carbonate, iron (as iron gluconate), and selenium (preferably as sodium selenate).
- the daily dosage can be administered in single or multiple unit dosages, preferably 1 to 10 unit dosages, more preferably 4-6 unit dosages.
- the constituents are combined to form a unit dosage in accordance with the amounts set forth in Table I, in which the broad, preferred, and more preferred range is are set forth as milligrams (mg) or % Daily Values.
- a composition of this invention can be specifically tailored for either men or women.
- a composition for men can have about 250 mg to about 750 mg arginine and about 15 mg to about 50 mg ginseng, preferably about 300 mg to about 600 mg arginine and about 20 mg to about 40 mg ginseng
- a composition for women can have about 200 mg to about 600 mg arginine and about 10 mg to about 25 mg ginseng, preferably about 300 mg to about 500 mg arginine and about 15 mg to about 20 mg ginseng.
- a composition for a man can comprise American ginseng and Korean ginseng
- a composition for a woman can comprise Korean ginseng but not American ginseng.
- compositions for a man may have a higher percentage of zinc and selenium, whereas a composition for a woman may have a higher percentage of calcium and iron.
- the composition can further comprise about 0 mg to about 50 mg damiana, preferably about 5 mg to about 15 mg, particularly for a composition for a woman.
- the dietary supplement of this invention is an aqueous composition
- it may be administered as single or multiple drinks having a volume of up to 500 milliliters (ml) or more.
- ml milliliters
- it is prepared as a drink having a volume of about 50 to about 300 ml with appropriate flavoring to be consumed either as a cold or hot beverage.
- it is flavored with a sweetener and a flavoring agents for easier consumption.
- a daily dose of two drinks each of about 100 ml has been found to be particularly useful.
- Table II sets forth the broad, preferred, and most preferred amounts in which the constituents are combined to form a unit dosage of 100 ml.
- a preferred composition for a man comprises about 500 to about 10000 mg arginine and about 25 to about 600 mg ginseng, preferably about 100 to about 400 mg ginseng, most preferably about 150 to about 250 mg ginseng.
- vitamins and minerals particularly some of the fat soluble vitamins, zinc, and selenium can be harmful in large doses.
- the daily dosage of such vitamins and minerals should not exceed 200% Daily Values.
- preferred daily dosages of the preferred minerals include about 15-30 mg zinc and about 70 mcg to about 140 mcg selenium.
- Preferred daily dosages of the preferred vitamin antioxidants include about 5000 IU to about 10000 IU Vitamin A, about 60 mg to about 120 mg Vitamin C, and about 30 IU to about 60 IU Vitamin E.
- Preferred daily dosages of the preferred B-vitamins include about 1.5 mg to about 3 mg thiamin, about 1.7 mg to about 3.4 mg riboflavin, about 2 mg to about 4 mg Vitamin B-6, and about 6 mcg to about 12 mcg Vitamin B-12.
- Preferred dosages of some other preferred vitamins include about 20 mg to about 40 mg niacin, about 400 mcg to about 800 mcg folate, about 300 mcg to about 600 mcg biotin, and about 10 mg to about 20 mg pantothenic acid.
- the dietary supplement can be administered in tablet, capsule, liquid, powder, nutritional bar or effervescent form.
- Methods of preparation of formulations for various forms of administration are known in the art and discussed in detail in Remington's Pharmaceutical Sciences. Eighteenth Edition (1990), incorporated herein by reference.
- Tablets can include components in addition to the active ingredients, such as diluents, binders, lubricants, glidants, disintegrants, coloring agents, and flavoring agents.
- Capsules for example, are made largely from gelatin, FD&C colorants, and sometimes an opacifying agent such as titanium dioxide.
- Effervescent tablets for example, comprise in addition to the active ingredients, sodium bicarbonate and an organic acid such as tartaric acid or citric acid. In the presence of water, these additives react, liberating carbon dioxide as a result of an acid-base reaction, which acts as a disintegrator and produces effervescence. Concentrations of the additives vary according to the acidic or basic nature of the active ingredients in order to ensure that an acid-base reaction occur upon contact of the effervescent tablet with water.
- the dietary supplement can also be formulated as a powder, which can be ingested directly or which can be ingested after reconstitution with an aqueous liquid. Preferably the supplement is administered in a capsule, effervescent tablet, or as a liquid tonic.
- the formulations can also comprise a flavoring agent.
- Another aspect of this invention is a method for improving sexual fitness in an animal, particularly human subject.
- the method comprises administering as unit dosage a composition of the invention, e.g., as a dietary supplement comprising the combination of L-Arginine, ginseng, and optionally ginkgo biloba.
- the regular administration of the composition over time results in improved sexual fitness, i.e., sexual function, in both males and females.
- Sexual fitness is determined by providing a subject taking the composition with a sexual function questionnaire.
- the questionnaire follows the Index of Female Sexual Function (IFSF). This is a 9-item, self-administered questionnaire. (See Urology 53: 481-486, 1999.)
- the questionnaire is directed at the level of discomfort during intercourse, the degree of vaginal dryness, the number of attempts at sexual intercourse, the rate and level of sexual desire, the level of satisfaction with a woman's sex life and relationship, the degree of clitoral sensation during sexual stimulation and the quality of orgasm.
- the administration of a composition of this invention results in improved sexual fitness as measured by one or more of the factors in the IFSF, e.g., increased clitoral sensation and improved sexual desire.
- the improvement in sexual fitness is determined by administering the International Index of Erectile Function (IIEF), a 15-question, validated, multidimensional, self-administered questionnaire.
- IIEF International Index of Erectile Function
- the questionnaire is directed at determining the ability to obtain an erection, the hardness of an erection, ability to penetrate a partner and maintain the erection, satisfaction level of intercourse, ability to ejaculate and experience orgasm, level of sexual desire, level of satisfaction with sex life and sexual relationship with a partner.
- the administration of a composition of this invention over time in accordance with the method of the invention results in improved sexual fitness as measured by one or more of the factors in the IIEF, e.g., improved ability to achieve an erection, an erection that can be maintained for a period of time that is longer than would occur without the administration of the dietary supplement, improvement in the quality of the orgasm for the subject.
- improved sexual fitness as measured by one or more of the factors in the IIEF, e.g., improved ability to achieve an erection, an erection that can be maintained for a period of time that is longer than would occur without the administration of the dietary supplement, improvement in the quality of the orgasm for the subject.
- the dietary supplement increases the production of nitric oxide (NO) by providing more substrate (L-arginine) for its production and upregulating the activity of nitric oxide synthase (NOS), the enzyme that cleaves L-arginine to form NO. NO in turn signals the creation of cGMP which triggers an erection in men.
- NO nitric oxide
- the dietary supplement helps improve the body's production of cGMP.
- female sexual function is accomplished physiologically in a similar manner.
- cGMP triggers lubrication and engorgement of the clitoral tissue.
- the dietary supplement of the invention is useful for improving sexual wellness, in both men and women.
- the dietary supplement can also be used in a method of medical treatment, such as, for example, the treatment of sexual dysfunction, or for the preparation of a medicament for such treatment.
- Example 7 simultaneous usage of ViagraTM (sildenafil citrate) and a dietary supplement comprising L-arginine, ginseng and ginkgo biloba improves sexual function in patients who did not respond satisfactorily to ViagraTM alone.
- ViagraTM which is currently prescribed in 25, 50 and 100 mg dosages for erectile dysfunction, exerts its effects by transiently inhibiting PDE5, a chemical in the body responsible for the degradation of cGMP in the corpus cavernosum (penis cavity).
- PDE5 a chemical in the body responsible for the degradation of cGMP in the corpus cavernosum (penis cavity).
- ViagraTM decreases the body's ability to breakdown cGMP for a short time, allowing more of it to accumulate. The resulting higher levels of cGMP increases the ease in achieving and maintaining an erection.
- Alprostadil is a smooth muscle relaxant. The binding of alprostadil to its receptors is accompanied by an increase in intracellular cAMP levels. Human cavernous smooth muscle cells respond to alprostadil by releasing intracellular calcium into the surrounding medium. Smooth muscle relaxation is associated with a reduction of the cytoplasmic free calcium concentration. Alprostadil also attenuates pre-synaptic noradrenaline release in the corpus cavernosum, which is essential for the maintenance of a flaccid and non-erect penis.
- yet another aspect of this invention is a method for enhancing the response of a male subject to a pharmaceutical composition which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum.
- the method is useful for subjects which have an unsatisfactory response to the pharmaceutical composition and wish to improve the efficacy of the pharmaceutical composition.
- the method comprises administering a daily dosage of a dietary supplement comprising, in at least one unit dosage, L-arginine, ginseng, and ginkgo biloba for a number of days sufficient to improve the ability of a male subject to achieve penile erection when the pharmaceutical composition is administered.
- a dietary supplement is administered for at least one day, more preferably at least about one week, and most preferably at least about two weeks.
- Other compounds which increase the levels of cGMP include, but are not limited to, alprostadil.
- the invention also provides a method for reducing the pharmaceutically effective dose of a pharmaceutical composition, such as, e.g., a composition comprising sildenafil citrate and/or alprostadil, which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum.
- a pharmaceutical composition such as, e.g., a composition comprising sildenafil citrate and/or alprostadil, which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum.
- the method is useful for subjects who, having experienced undesirable side effects with their current dosage of the pharmaceutical composition, wish to reduce the dosage to avoid the side effects yet maintain a favorable level of efficacy.
- the method is also useful for subjects who do not have problems with side effects from the current dosage of the pharmaceutical composition but wish to achieve the same level of efficacy with a reduced dosage for reasons of cost, preference for natural products, etc.
- the method comprises administering, to a male subject being treated with a first dosage of the pharmaceutical composition, a daily dosage of a dietary supplement comprising, in at least one unit dosage, L-arginine, ginseng, and ginkgo biloba for a time sufficient to enhance the effects on said cGMP levels mediated by a first dosage of a pharmaceutical composition prescribed for erectile dysfunction; and adjusting said first dosage to a second dosage which exerts the same effects on said cGMP levels of said first dosage prior to commencement of said daily dosage of said dietary supplement.
- Another preferred aspect of the invention is a method of ameliorating erectile dysfunction, comprising administering a daily dosage of a dietary supplement comprising L-arginine, ginseng, and ginkgo biloba and administering, when an erection is desired, a pharmaceutical composition, such as, e.g., a composition comprising sildenafil citrate and/or alprostadil, which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum.
- the pharmaceutical composition is administered less than about 6 hours before attempting intercourse, preferably from about 4 hours to about 0.5 hour before sexual activity, and most preferably about 1 hour before sexual activity.
- Preferred dosages of the pharmaceutical composition are about one fourth of the dosages normally prescribed, preferably about one half of the normal dosages.
- preferred dosages of sildenafil citrate for this method include, but are not limited to, about 6.25 mg, 12.5 mg, 25 mg, and 50 mg dosages.
- the administration of the composition of this invention is carried out on a daily basis for a period of time sufficient to improve sexual fitness.
- the time and amount administered will vary from subject to subject and will be influenced by the age of the subject, whether male or female. Generally, the younger the subject, the sooner the results will be seen and the smaller the amount needed to see the results. As a subject ages, the composition will have to be administered over a longer period of time and in larger amounts for a subject to experience results.
- the composition is preferably administered for at least two days. More preferably it is administered for at least about a one week period, even more preferably at least about a two week period, and most preferably for at least about a four week period.
- the composition is administered in either the tablet, capsule or liquid form in accordance with the composition discussed herein before.
- a desired daily dosage is achieved by administering an appropriate quantity of unit dosages.
- the amounts administered on a daily basis will be between about 500 mg-10000 mg of L-arginine per day, preferably about 2000 to 5000 mg of L-arginine a day.
- the ginseng is administered at a rate of about 25 mg to about 600 mg per day preferably about 100 to about 400 mg per day.
- the ginkgo biloba is administered at a rate of about 8 mg to 300 mg per day, preferably about 50 to about 250 mg per day.
- up to 200 percent of the daily values of antioxidant vitamins, vitamin B complex and certain minerals, as discussed hereinbefore, are administered along with the dietary supplement combination.
- the supplement can be administered weekly or even monthly, but daily administration is preferred, preferably on an empty stomach.
- the daily dosage can be a single unit dosage or a multiple unit dosage.
- a daily dosage can be from 1 to 10 capsules or 1 to 4 100 ml beverages daily.
- the daily dosage is 6 capsules or 2 100 ml beverages.
- the daily dosage is administered in two unit dosages, preferably upon waking and at bedtime.
- Another aspect of this invention is a method for preparing a composition useful for improving sexual fitness.
- the process comprises combining L-arginine with a material for increasing nitric acid synthase activity (e.g., ginseng) and optionally (a) a material that promotes vascular circulation (e.g., ginkgo biloba) and (b) additional dietary supplements such as vitamins and minerals.
- a material for increasing nitric acid synthase activity e.g., ginseng
- a material that promotes vascular circulation e.g., ginkgo biloba
- additional dietary supplements such as vitamins and minerals.
- Still another aspect of this invention is an article of manufacture that is a composition in accordance with this invention in combination with labeling that the composition is to be taken for sexual fitness.
- the article is simply a container such as a bottle or box containing unit dosage forms (e.g., tablets, capsules) with labeling indicating the rate at which the unit dosage should be consumed, e.g., see Examples 1-3.
- the dietary supplement is provided in a 6 gel cap serving to be taken daily, preferably by a human male, for at least 2-3 weeks, preferably on an empty stomach, and comprises the following components per serving: Vitamin A 5000 IU Vitamin C 60 mg Vitamin E 30 IU Thiamin 1.5 mg Riboflavin 1.7 mg Niacin 20 mg Vitamin B-6 2 mg Folate 400 mcg Vitamin B-12 6 mcg Biotin 300 mcg Pantothenic acid 10 mg Zinc 15 mg Selenium 70 mcg L-arginine 3000 mg American Ginseng-standardized 100 mg (5% ginsenosides) Korean Ginseng-standardized 100 mg (30% ginsenoside) Ginkgo Biloba-standardized 50 mg (24% flavone glycosides, 6% terpene lactones)
- the dietary supplement is provided in two 100 ml servings to be taken daily, preferably by a human male, for at least 2-3 weeks, preferably on an empty stomach, and comprises the following components per serving: Vitamin A 5000 IU Vitamin C 60 mg Vitamin E 30 IU Thiamin 1.5 mg Riboflavin 1.7 mg Niacin 20 mg Vitamin B-6 2 mg Folate 400 mcg Vitamin B-12 6 mcg Biotin 300 mcg Pantothenic acid 10 mg Zinc 7.5 mg Selenium 70 mcg L-arginine 1500 mg American Ginseng-root (1:5) 100 mg Korean Ginseng-root (1:5) 100 mg Ginkgo Biloba-fresh leaf (1:2) 100 mg
- the dietary supplement is provided in a 6 gel cap serving to be taken daily, preferably by a human female, for at least 2-3 weeks, preferably on an empty stomach, and comprises the following components per serving: Vitamin A 5000 IU Vitamin C 60 mg Vitamin E 30 IU Thiamin 1.5 mg Riboflavin 1.7 mg Niacin 20 mg Vitamin B-6 2 mg Folate 400 mcg Vitamin B-12 6 mcg Biotin 300 mcg Pantothenic acid 10 mg Calcium 500 mg Iron 9 mg Zinc 7.5 mg L-arginine 2500 mg Korean Ginseng-standardized 100 mg (30% ginsenosides) Ginkgo Biloba-standardized 50 mg (24% flavone glycosides, 6% terpene lactones) Damiana leaves 50 mg (Turnera Aphrodisiaca)
- a healthy man takes 3,000 mg L-arginine as a separate dietary supplement daily on an empty stomach for a minimum of 2-3 weeks.
- Example 1 Male subjects with mild to moderate erectile dysfunction were instructed on the use and regimen of the dietary supplement of Example 1 and were requested to fill out a baseline SFQ survey. Subjects started a twice-per-day regimen of the dietary supplement, once in the morning upon waking and once in the evening at bedtime. A 4-week supply of the dietary supplement was provided. After completing the 4-week regimen, patients were instructed to complete a 4-week SFQ survey and return to the test center for follow-up evaluation and examination.
- the SFQ was used as the primary test instrument.
- the SFQ is a self-administered questionnaire beginning with the validated IIEF (International Index of Erectile Function used with permission) test instrument and including other validated test instruments designed to measure changes in erectile function, sexual function, and quality of life.
- IIEF International Index of Erectile Function used with permission
- FSFI Female Sexual Function Index
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides methods and compositions for maintaining a state of wellness in a human by providing a dietary supplement comprising L-arginine, alone or in combination with ginseng and ginkgo biloba and/or additional nutritional supplements. The invention provides a unique blend of components that, in combination, synergistically bestow sexual wellness upon a human when taken regularly as a dietary supplement.
Description
- This application is a continuation-in-part of PCT International Patent Application No. PCT/US99/07427 filed internationally on Apr. 2, 1999 which claims priority to U.S. Provisional Applications 60/080,009 filed Apr. 3, 1998 and 60/093,164 filed Jul. 17, 1998.
- 1. Technical Field
- This invention relates to the maintenance of a state of wellness in which sexual health is improved.
- 2. Background
- Quality of life is increasingly valued in today's society. Proper nutrition and exercise, and healthy sexual function contribute to maintain an overall state of wellbeing, which can serve to manage stress, maintain a properly functioning immune system, protect against disease, maintain a positive mental outlook, and generally to enable one to feel good and enjoy life.
- It has been found that the combination of L-arginine, ginseng, and optionally, ginkgo biloba when administered to a human in combination improves the blood circulation and improves the sexual, mental, and cardiac health of an individual. The invention provides methods and compositions for maintaining a state of wellness in an animal by providing a dietary supplement comprising L-arginine, in combination with ginseng and optionally ginkgo biloba and/or additional nutritional supplements. The invention provides a unique blend of components that, in combination, synergistically bestow sexual wellness upon an animal when taken regularly as a dietary supplement alone, or in combination with a pharmaceutical composition which facilitates smooth muscle relaxation and vascular dilatation.
- One aspect of the invention is a composition for improving sexual fitness in an animal. The composition comprises (a) a metabolic precursor to nitric oxide. (b) a material for increasing nitric oxide synthase activity, and optionally (c) a material to promote vascular circulation, particularly microvascular circulation. Additional dietary supplements such as vitamins and minerals can also be included.
- Another aspect of the invention is a method for improving sexual function in an animal. The method comprises administering the composition described above.
- A third aspect of the invention is a method of treating sexual dysfunction in a male or female, e.g., erectile dysfunction in the male. The method comprises administering the composition described above.
- Yet another aspect of the invention is a method for preparing a composition useful for improving sexual fitness. The process comprises combining the components of the composition described above, preferably into unit dosage forms.
- A fifth aspect of the invention is an article of manufacture comprising the composition described above in combination with labeling that the composition is to be taken for sexual fitness.
- The compositions and methods of the invention provide a dietary supplement useful for maintaining a state of wellness in an animal, preferably a laboratory animal or domesticated animal, even more preferably a human, whether male or female.
- The composition and method of the invention are particularly useful for improving sexual fitness in both males and females. The composition and method are particularly useful for people who want to remain sexually active as they grow older.
- The composition of the invention comprises two, and preferably three, components: (a) a metabolic precursor to nitric oxide. (b) a material for increasing nitric oxide synthase activity, and optionally (c) a material to promote vascular circulation, particularly microvascular circulation. Preferably, the composition is a dietary supplement that is delivered over time to achieve the desired results.
- A preferred dietary supplement of the invention comprises a combination of arginine, ginseng, and optionally ginkgo biloba, which is useful for improving blood flow and circulation. Improved blood flow is important for maintaining good sexual health. The compositions and methods of the invention improve sexual wellness without any undesirable side effects such as headache, nausea, gastric upset, chest pain, dizziness, vision disturbance, or change in blood pressure.
- The Composition
- The main component of the composition of this invention is a metabolic precursor to nitric oxide (NO), such as, for example, organic nitrates and nitrites and other compounds that are capable of conversion to nitric oxide. Many of such precursors are also called nitrovasodilators. Examples of organic nitrates include isoamyl nitrate, nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate and pentaerythritol. Preferably, the precursor to NO is arginine. Arginine is an essential amino acid having the chemical name 2-amino-5-guanidinovaleric acid. It is preferably used in the physiologically active form which is designated as the “L” form. The compound is readily available from various sources in the commercial market place such as from Sigma Chemical Company or Aldrich Chemical Company in a pharmaceutical grade. It generally is available as a powder that generally is associated with two moles of water and forms monoclinic plates. Preferably the L-arginine in the composition is free of other amino acids, peptides and proteins that would interfere with the uptake of L-arginine into the animal's system.
- The second component present in the composition is a material that increases nitric oxide synthase (NOS) activity. The increase in NOS activity may result from the increase in the quantity of NOS in the system or from an improvement in the level of activity of NOS or by some other manner. A preferred material is ginseng. Ginseng is material extracted from the root of a plant that is a member of the ginseng family (Araliaceae), genus Panax. Ginseng plants grow in Asia and North America.P. ginseng grows in Northern China (Chinese ginseng) and Korea (Korean ginseng). The material extracted from the root is referred to as white ginseng or red ginseng. The former is dried P. ginseng root, while the latter is P. ginseng root steamed in caramel. American ginseng (P. quinquefolium) generally grows in the northern U.S. and Canada. Other relatives include Japanese ginseng (P. japonicum), San-Chi ginseng (P. notoginseng), Himalayan ginseng (P. pseudoginseng, ssp. himalaicus var argustifolius) and Siberian ginseng (Eleutherococcus senticosus).
- The ginseng component in the composition is usually standardized ginseng obtained from plants originating from one or more geographical areas and comprises, in total, about 1% to about 50% ginsenosides, preferably about 10% to about 35% ginsenosides, more preferably about 15% to about 20% ginsenosides, most preferably about 17.5% ginsenosides. Preferably the ginseng component comprises American ginseng and Korean ginseng. The American ginseng comprises about 1% to about 50% ginsenosides, preferably about 1% to about 10% ginsenosides, more preferably about 5% ginsenosides. The Korean ginseng comprises about 1% to about 50% ginsenosides, preferably about 10% to about 40% ginsenosides, more preferably about 30% ginsenosides. The ginseng component in a liquid or tonic is usually one or more extracts of ginseng from various geographical areas having a ratio of herb to solvent when extracted of about 1:2 to about 1:10, preferably about 1:5.
- The various types of ginseng are available on the commercial market and are available from various sources, such as, for example, East Earth Herb and Natural Sourcing Solutions, Inc. The types and relative abundance of the chemical constituents of ginseng depend on the species, the part of the plant, the place of origin, the method of cultivation, and the technique of extraction used to obtain the ginseng. Different types of ginseng may have slightly different constituent profiles, but the type of ginseng used in this composition will be the material extracted fromPanax ginseng or Panax quinquefolius. Preferably a mixture of American ginseng and Korean ginseng is employed.
- The composition of the ginseng extracted from the roots of the various plants is quite similar among the different species used. Generally the ginseng will contain typical ginsenosides. A further discussion of the constituents of the various types of ginseng may be found in the American Chemical Society publication entitled “Folk Medicine: The Art and the Science,” edited by Richard P. Steiner, University of Utah (1986).
- Preferably, the composition of this invention also comprises a material that promotes vascular circulation in the person receiving the composition. This material may be a pharmaceutical or a dietary supplement or herb. Some materials that promote vascular circulation are known as vasodilators, e.g., hydralazine, minoxidil, sodium nitroprusside, diazoxide, phentolamine mesylate, phentolamine hydrochloride, phenoxybenzamine, yohimbine, nitroglycerine, thymoxamine, imipramine, isoxsuprine, naftidrofuryl, tolazoline, papaverine, and calcium channel blockers that act as vasodilators, such as nifedipine, nicardipine, nimodipine, verapamil and diltiazem. A particularly preferred material that promotes vascular circulation is Ginkgo biloba. Ginkgo biloba is extracted from the leaves of the ginkgo biloba tree. The leaves are harvested in late summer when the leaves have the highest level of active compounds. The extract is semipurified to remove undesirable compounds which do not contribute to the desired health benefits. The material can be highly concentrated and standardized to a known and consistent level of the active principals known as ginkgolides. Ginkgo biloba is readily available from the various sources throughout the herbal medicine industry, such as, for example, East Earth Herb and Natural Sourcing Solutions, Inc.
- The ginkgo component in the composition as a solid, e.g., a tablet, capsule, or powder, is usually standardized ginkgo and comprises about 1% to about 50% flavone glycosides, preferably about 15% to about 30% flavone glycosides, more preferably about 24% flavone glycosides, and about 1% to about 20% terpene lactones, preferably about 5% to about 10% terpene lactones, more preferably about 6% terpene lactones. The ginkgo component in a liquid or tonic is usually an extract having a ratio of herb to solvent when extracted of about 1:2 to about 1:5, preferably about 1:2.
- A dietary supplement composition comprising the combination of L-arginine, ginseng, and ginkgo biloba is administered to a subject orally as a capsule, tablet, powder or as an aqueous composition. If administered as a capsule, tablet, or powder, an amount of each of the three constituents is mixed in accordance with standard pharmaceutical practice to form a unit dosage that can be swallowed by taking water with the unit dosage. (See, for example, “Remington, The Science and Practice of Pharmacy,” Nineteenth Edition, Mack Publishing co. for a discussion of the preparation of tablets and capsules/chapters 91-93). In general, the size of the tablet or capsule will be less than about a gram to maximize the ease of swallowing. In addition to the three major components of the composition of this invention, a dietary supplement also may contain antioxidant vitamins, vitamin-B-complex, and certain minerals. These additional constituents may be present in an amount up to about 100% of the daily values for each constituent for a male or female. By “daily values” is meant the Reference Daily Intake (RDI) as defined in 21 CFR §101.9(c)(8)(iv). Antioxidant vitamins include vitamins A (preferably as palmitate), C (preferably as ascorbic acid) and E (preferably as dl α tocopherol acetate). Vitamin-B complex includes thiamin (preferably as the mononitrate), riboflavin, niacin (preferably is niacinamide), vitamin B-6 (preferably as pyroxidine HCl), folate (preferable as folic acid), vitamin B-12 (preferably as cyanocobalamin), biotin, and pantothenic acid (preferably as calcium pantothenate). Minerals include zinc (preferably as zinc gluconate), calcium (preferably as calcium carbonate, iron (as iron gluconate), and selenium (preferably as sodium selenate).
- Where a dietary supplement of this invention is administered in tablet, capsule, or powder form, the daily dosage can be administered in single or multiple unit dosages, preferably 1 to 10 unit dosages, more preferably 4-6 unit dosages. The constituents are combined to form a unit dosage in accordance with the amounts set forth in Table I, in which the broad, preferred, and more preferred range is are set forth as milligrams (mg) or % Daily Values.
TABLE I Constituent Broad Preferred More Preferred Arginine 200-750 mg 300-600 mg 450-550 mg Ginseng 10-50 mg 15-40 mg 15-35 mg Ginkgo biloba 0-15 mg 5-10 mg 5-10 mg Antioxidant vitamins 0-100% 4‥50% 10-20% B-complex 0-100% 5-50% 10-20% Minerals 0-100% 5-30% 10-20% - A composition of this invention can be specifically tailored for either men or women. For example, a composition for men can have about 250 mg to about 750 mg arginine and about 15 mg to about 50 mg ginseng, preferably about 300 mg to about 600 mg arginine and about 20 mg to about 40 mg ginseng, whereas a composition for women can have about 200 mg to about 600 mg arginine and about 10 mg to about 25 mg ginseng, preferably about 300 mg to about 500 mg arginine and about 15 mg to about 20 mg ginseng. As another example, a composition for a man can comprise American ginseng and Korean ginseng, whereas a composition for a woman can comprise Korean ginseng but not American ginseng. In addition, a composition for a man may have a higher percentage of zinc and selenium, whereas a composition for a woman may have a higher percentage of calcium and iron. Furthermore, the composition can further comprise about 0 mg to about 50 mg damiana, preferably about 5 mg to about 15 mg, particularly for a composition for a woman.
- Where the dietary supplement of this invention is an aqueous composition, it may be administered as single or multiple drinks having a volume of up to 500 milliliters (ml) or more. Preferably however it is prepared as a drink having a volume of about 50 to about 300 ml with appropriate flavoring to be consumed either as a cold or hot beverage. Preferably it is flavored with a sweetener and a flavoring agents for easier consumption. A daily dose of two drinks each of about 100 ml has been found to be particularly useful. Table II sets forth the broad, preferred, and most preferred amounts in which the constituents are combined to form a unit dosage of 100 ml.
TABLE II Constituent Broad Preferred More Preferred Arginine 400-10000 mg 750-3000 mg 1000-2000 mg Ginseng 15-600 mg 25-400 mg 50-200 mg GBE 0-300 mg 10-250 mg 25-100 mg Antioxidant vita- 0-200% 25-150% 50-100% mins B-complex 0-200% 25-150% 50-100% Minerals 0-100% 25-100% 50-100% - A preferred composition for a man comprises about 500 to about 10000 mg arginine and about 25 to about 600 mg ginseng, preferably about 100 to about 400 mg ginseng, most preferably about 150 to about 250 mg ginseng.
- It should be appreciated that some vitamins and minerals, particularly some of the fat soluble vitamins, zinc, and selenium can be harmful in large doses. Thus, preferably the daily dosage of such vitamins and minerals should not exceed 200% Daily Values. If present, preferred daily dosages of the preferred minerals include about 15-30 mg zinc and about 70 mcg to about 140 mcg selenium. Preferred daily dosages of the preferred vitamin antioxidants include about 5000 IU to about 10000 IU Vitamin A, about 60 mg to about 120 mg Vitamin C, and about 30 IU to about 60 IU Vitamin E. Preferred daily dosages of the preferred B-vitamins include about 1.5 mg to about 3 mg thiamin, about 1.7 mg to about 3.4 mg riboflavin, about 2 mg to about 4 mg Vitamin B-6, and about 6 mcg to about 12 mcg Vitamin B-12. Preferred dosages of some other preferred vitamins include about 20 mg to about 40 mg niacin, about 400 mcg to about 800 mcg folate, about 300 mcg to about 600 mcg biotin, and about 10 mg to about 20 mg pantothenic acid.
- The dietary supplement can be administered in tablet, capsule, liquid, powder, nutritional bar or effervescent form. Methods of preparation of formulations for various forms of administration are known in the art and discussed in detail inRemington's Pharmaceutical Sciences. Eighteenth Edition (1990), incorporated herein by reference. Tablets, for example, can include components in addition to the active ingredients, such as diluents, binders, lubricants, glidants, disintegrants, coloring agents, and flavoring agents. Capsules, for example, are made largely from gelatin, FD&C colorants, and sometimes an opacifying agent such as titanium dioxide. Effervescent tablets, for example, comprise in addition to the active ingredients, sodium bicarbonate and an organic acid such as tartaric acid or citric acid. In the presence of water, these additives react, liberating carbon dioxide as a result of an acid-base reaction, which acts as a disintegrator and produces effervescence. Concentrations of the additives vary according to the acidic or basic nature of the active ingredients in order to ensure that an acid-base reaction occur upon contact of the effervescent tablet with water. The dietary supplement can also be formulated as a powder, which can be ingested directly or which can be ingested after reconstitution with an aqueous liquid. Preferably the supplement is administered in a capsule, effervescent tablet, or as a liquid tonic. The formulations can also comprise a flavoring agent.
- Method of Administration
- Another aspect of this invention is a method for improving sexual fitness in an animal, particularly human subject. The method comprises administering as unit dosage a composition of the invention, e.g., as a dietary supplement comprising the combination of L-Arginine, ginseng, and optionally ginkgo biloba.
- The regular administration of the composition over time results in improved sexual fitness, i.e., sexual function, in both males and females. Sexual fitness is determined by providing a subject taking the composition with a sexual function questionnaire. For women, the questionnaire follows theIndex of Female Sexual Function (IFSF). This is a 9-item, self-administered questionnaire. (See Urology 53: 481-486, 1999.) The questionnaire is directed at the level of discomfort during intercourse, the degree of vaginal dryness, the number of attempts at sexual intercourse, the rate and level of sexual desire, the level of satisfaction with a woman's sex life and relationship, the degree of clitoral sensation during sexual stimulation and the quality of orgasm. In general, the administration of a composition of this invention results in improved sexual fitness as measured by one or more of the factors in the IFSF, e.g., increased clitoral sensation and improved sexual desire.
- For men, the improvement in sexual fitness is determined by administering theInternational Index of Erectile Function (IIEF), a 15-question, validated, multidimensional, self-administered questionnaire. (See Urology: 49, 822-830.) The questionnaire is directed at determining the ability to obtain an erection, the hardness of an erection, ability to penetrate a partner and maintain the erection, satisfaction level of intercourse, ability to ejaculate and experience orgasm, level of sexual desire, level of satisfaction with sex life and sexual relationship with a partner. In general, the administration of a composition of this invention over time in accordance with the method of the invention results in improved sexual fitness as measured by one or more of the factors in the IIEF, e.g., improved ability to achieve an erection, an erection that can be maintained for a period of time that is longer than would occur without the administration of the dietary supplement, improvement in the quality of the orgasm for the subject. In addition, it is found that upon exertion by any significant exercise the subject's breathing and ability to breathe is improved.
- It is believed that the dietary supplement increases the production of nitric oxide (NO) by providing more substrate (L-arginine) for its production and upregulating the activity of nitric oxide synthase (NOS), the enzyme that cleaves L-arginine to form NO. NO in turn signals the creation of cGMP which triggers an erection in men. The dietary supplement helps improve the body's production of cGMP. It is believed that female sexual function is accomplished physiologically in a similar manner. For example, cGMP triggers lubrication and engorgement of the clitoral tissue. Thus, the dietary supplement of the invention is useful for improving sexual wellness, in both men and women. The dietary supplement can also be used in a method of medical treatment, such as, for example, the treatment of sexual dysfunction, or for the preparation of a medicament for such treatment.
- As shown in Example 7, simultaneous usage of Viagra™ (sildenafil citrate) and a dietary supplement comprising L-arginine, ginseng and ginkgo biloba improves sexual function in patients who did not respond satisfactorily to Viagra™ alone. Viagra™, which is currently prescribed in 25, 50 and 100 mg dosages for erectile dysfunction, exerts its effects by transiently inhibiting PDE5, a chemical in the body responsible for the degradation of cGMP in the corpus cavernosum (penis cavity). In essence, Viagra™ decreases the body's ability to breakdown cGMP for a short time, allowing more of it to accumulate. The resulting higher levels of cGMP increases the ease in achieving and maintaining an erection.
- Alprostadil is a smooth muscle relaxant. The binding of alprostadil to its receptors is accompanied by an increase in intracellular cAMP levels. Human cavernous smooth muscle cells respond to alprostadil by releasing intracellular calcium into the surrounding medium. Smooth muscle relaxation is associated with a reduction of the cytoplasmic free calcium concentration. Alprostadil also attenuates pre-synaptic noradrenaline release in the corpus cavernosum, which is essential for the maintenance of a flaccid and non-erect penis.
- The dietary supplement, Viagra™, and alprostadil all work to facilitate smooth muscle relaxation and vascular dilatation. Thus, yet another aspect of this invention is a method for enhancing the response of a male subject to a pharmaceutical composition which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum. The method is useful for subjects which have an unsatisfactory response to the pharmaceutical composition and wish to improve the efficacy of the pharmaceutical composition. The method comprises administering a daily dosage of a dietary supplement comprising, in at least one unit dosage, L-arginine, ginseng, and ginkgo biloba for a number of days sufficient to improve the ability of a male subject to achieve penile erection when the pharmaceutical composition is administered. Preferably the dietary supplement is administered for at least one day, more preferably at least about one week, and most preferably at least about two weeks. Other compounds which increase the levels of cGMP include, but are not limited to, alprostadil.
- The invention also provides a method for reducing the pharmaceutically effective dose of a pharmaceutical composition, such as, e.g., a composition comprising sildenafil citrate and/or alprostadil, which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum. The method is useful for subjects who, having experienced undesirable side effects with their current dosage of the pharmaceutical composition, wish to reduce the dosage to avoid the side effects yet maintain a favorable level of efficacy. The method is also useful for subjects who do not have problems with side effects from the current dosage of the pharmaceutical composition but wish to achieve the same level of efficacy with a reduced dosage for reasons of cost, preference for natural products, etc. The method comprises administering, to a male subject being treated with a first dosage of the pharmaceutical composition, a daily dosage of a dietary supplement comprising, in at least one unit dosage, L-arginine, ginseng, and ginkgo biloba for a time sufficient to enhance the effects on said cGMP levels mediated by a first dosage of a pharmaceutical composition prescribed for erectile dysfunction; and adjusting said first dosage to a second dosage which exerts the same effects on said cGMP levels of said first dosage prior to commencement of said daily dosage of said dietary supplement.
- Another preferred aspect of the invention is a method of ameliorating erectile dysfunction, comprising administering a daily dosage of a dietary supplement comprising L-arginine, ginseng, and ginkgo biloba and administering, when an erection is desired, a pharmaceutical composition, such as, e.g., a composition comprising sildenafil citrate and/or alprostadil, which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum. Typically, the pharmaceutical composition is administered less than about 6 hours before attempting intercourse, preferably from about 4 hours to about 0.5 hour before sexual activity, and most preferably about 1 hour before sexual activity. Preferred dosages of the pharmaceutical composition are about one fourth of the dosages normally prescribed, preferably about one half of the normal dosages. For example, preferred dosages of sildenafil citrate for this method include, but are not limited to, about 6.25 mg, 12.5 mg, 25 mg, and 50 mg dosages.
- In general, the administration of the composition of this invention is carried out on a daily basis for a period of time sufficient to improve sexual fitness. The time and amount administered will vary from subject to subject and will be influenced by the age of the subject, whether male or female. Generally, the younger the subject, the sooner the results will be seen and the smaller the amount needed to see the results. As a subject ages, the composition will have to be administered over a longer period of time and in larger amounts for a subject to experience results. The composition is preferably administered for at least two days. More preferably it is administered for at least about a one week period, even more preferably at least about a two week period, and most preferably for at least about a four week period. By ingesting the composition over an extended period of time making the dietary supplement an addition to the diet on a sustained basis, sexual fitness will be improved generally. In administering the composition to an individual, the composition is administered in either the tablet, capsule or liquid form in accordance with the composition discussed herein before. Typically, a desired daily dosage is achieved by administering an appropriate quantity of unit dosages. Generally the amounts administered on a daily basis will be between about 500 mg-10000 mg of L-arginine per day, preferably about 2000 to 5000 mg of L-arginine a day. The ginseng is administered at a rate of about 25 mg to about 600 mg per day preferably about 100 to about 400 mg per day. The ginkgo biloba is administered at a rate of about 8 mg to 300 mg per day, preferably about 50 to about 250 mg per day. Optionally up to 200 percent of the daily values of antioxidant vitamins, vitamin B complex and certain minerals, as discussed hereinbefore, are administered along with the dietary supplement combination.
- The supplement can be administered weekly or even monthly, but daily administration is preferred, preferably on an empty stomach. The daily dosage can be a single unit dosage or a multiple unit dosage. For example, a daily dosage can be from 1 to 10 capsules or 1 to 4 100 ml beverages daily. Preferably the daily dosage is 6 capsules or 2 100 ml beverages. Preferably the daily dosage is administered in two unit dosages, preferably upon waking and at bedtime. Some preferred dietary supplements are discussed further in Examples 1-3.
- Another aspect of this invention is a method for preparing a composition useful for improving sexual fitness. The process comprises combining L-arginine with a material for increasing nitric acid synthase activity (e.g., ginseng) and optionally (a) a material that promotes vascular circulation (e.g., ginkgo biloba) and (b) additional dietary supplements such as vitamins and minerals. The mixture is formed into unit dosage forms and labeled as being useful for improving sexual fitness.
- Still another aspect of this invention is an article of manufacture that is a composition in accordance with this invention in combination with labeling that the composition is to be taken for sexual fitness. The article is simply a container such as a bottle or box containing unit dosage forms (e.g., tablets, capsules) with labeling indicating the rate at which the unit dosage should be consumed, e.g., see Examples 1-3.
- Dietary Supplement in Gel Cap Form
- The dietary supplement is provided in a 6 gel cap serving to be taken daily, preferably by a human male, for at least 2-3 weeks, preferably on an empty stomach, and comprises the following components per serving:
Vitamin A 5000 IU Vitamin C 60 mg Vitamin E 30 IU Thiamin 1.5 mg Riboflavin 1.7 mg Niacin 20 mg Vitamin B-6 2 mg Folate 400 mcg Vitamin B-12 6 mcg Biotin 300 mcg Pantothenic acid 10 mg Zinc 15 mg Selenium 70 mcg L-arginine 3000 mg American Ginseng-standardized 100 mg (5% ginsenosides) Korean Ginseng-standardized 100 mg (30% ginsenoside) Ginkgo Biloba-standardized 50 mg (24% flavone glycosides, 6% terpene lactones) - Dietary Supplement in Tonic Form
- The dietary supplement is provided in two 100 ml servings to be taken daily, preferably by a human male, for at least 2-3 weeks, preferably on an empty stomach, and comprises the following components per serving:
Vitamin A 5000 IU Vitamin C 60 mg Vitamin E 30 IU Thiamin 1.5 mg Riboflavin 1.7 mg Niacin 20 mg Vitamin B-6 2 mg Folate 400 mcg Vitamin B-12 6 mcg Biotin 300 mcg Pantothenic acid 10 mg Zinc 7.5 mg Selenium 70 mcg L-arginine 1500 mg American Ginseng-root (1:5) 100 mg Korean Ginseng-root (1:5) 100 mg Ginkgo Biloba-fresh leaf (1:2) 100 mg - Dietary Supplement in Gel Cap Form
- The dietary supplement is provided in a 6 gel cap serving to be taken daily, preferably by a human female, for at least 2-3 weeks, preferably on an empty stomach, and comprises the following components per serving:
Vitamin A 5000 IU Vitamin C 60 mg Vitamin E 30 IU Thiamin 1.5 mg Riboflavin 1.7 mg Niacin 20 mg Vitamin B-6 2 mg Folate 400 mcg Vitamin B-12 6 mcg Biotin 300 mcg Pantothenic acid 10 mg Calcium 500 mg Iron 9 mg Zinc 7.5 mg L-arginine 2500 mg Korean Ginseng-standardized 100 mg (30% ginsenosides) Ginkgo Biloba-standardized 50 mg (24% flavone glycosides, 6% terpene lactones) Damiana leaves 50 mg (Turnera Aphrodisiaca) - Regular Administration of L-arginine to Maintain a State of Wellness thereby Reducing the Likelihood of Developing a Headache
- A healthy man takes 3,000 mg L-arginine as a separate dietary supplement daily on an empty stomach for a minimum of 2-3 weeks.
- Regular Administration of L-arginine in Combination with Ginseng and Ginkgo Biloba to Maintain a State of Wellness
- 18 healthy men, age 29 to 44, were instructed to take two 100 ml servings of the dietary supplement described in Example 2 daily on an empty stomach for eight weeks. Survey data was collected before and after the men begin taking the dietary supplement. The volunteers noted a 29 to 33% increase in quality of orgasm, sexual confidence and sexual stamina. Penile hardness ratings and sexual enjoyment ratings increased by 13%. Ease of breathing after exertion also increased by 29%. Frequency of headaches decreased.
- Administration of L-arginine in Combination with Ginseng and Ginkgo Biloba in Men with Erectile Dysfunction
- Male subjects with mild to moderate erectile dysfunction were instructed on the use and regimen of the dietary supplement of Example 1 and were requested to fill out a baseline SFQ survey. Subjects started a twice-per-day regimen of the dietary supplement, once in the morning upon waking and once in the evening at bedtime. A 4-week supply of the dietary supplement was provided. After completing the 4-week regimen, patients were instructed to complete a 4-week SFQ survey and return to the test center for follow-up evaluation and examination.
- The SFQ was used as the primary test instrument. The SFQ is a self-administered questionnaire beginning with the validated IIEF (International Index of Erectile Function used with permission) test instrument and including other validated test instruments designed to measure changes in erectile function, sexual function, and quality of life. (Rosen et al., Urology, June 1997, 49(6):822-830; Derogatis LR, J Sex Marital Ther, 1997, 23(4):291-304; Conte HR, Arch Sex Behav, December 1983, 12(6):555-576; Jenkinson et al., BMJ, May 29, 1993, 306(6890):1437-1440; Garrarr et al., BMJ, May 29, 1993, 306(6890):1440-1444) In addition, the SFQ included questions regarding subject's activities and condition during the trial period.
Subject Group Profile at Baseline Total # of subjects 25 Age range 40-77 # hypertensive 19 # diabetes mellitus 4 - Patient responses to SFQ survey questions at 4 weeks were compared to SFQ responses at baseline. A comparison analysis was performed for those subjects whose degree of erectile dysfunction were mild to moderate as characterized by a minimal baseline score of 2. For each SFQ variable, a comparison was made of those subjects who initially had a baseline score of at least 2 to their 4 week score on the same variable. The results were then pooled, summarized, and evaluated to reflect the percentage of subjects with improvement in each of the SFQ question variables. 88.9% of subjects showed improvement in the ability to maintain erection during intercourse. 75.0% of subjects showed improvement in satisfaction with overall sex life. 20.0% of subjects showed improvement in number of orgasms. 12.5% of subjects showed improvement in the number of times attempted intercourse.
- There were no significant changes in blood pressure or other significant side effects as noted by net % of patients reporting increase or decrease as follows:
Headaches: −4.8% Nausea: −4.8% Stomach upset: −14.3% Chest pain: 0% Dizziness: 0% Vision disturbance: 0% - Administration of L-arginine in Combination with Ginseng and Ginkgo Biloba in Patients that had not Responded Satisfactorily to Viagra™
- Six patients which had not responded satisfactorily to Viagra™ (sildenafil citrate) were asked to use the dietary supplement of Example 1 for 4 weeks on a daily basis and to try Viagra™ again as they felt the need. Typically patients used Viagra™ about 1 hour prior to engaging in sexual activity. Patients were using either 50 or 100 mg dosages of Viagra™. 4 out of 6 showed dramatic improvement based on an increase in several key IIEF variables, such as erection frequency, erection firmness, penetration ability, maintenance frequency, and maintenance ability.
- Female Clinical Study Regarding Sexual Fitness
- A double-blind, placebo-controlled study was carried out examining the role of dietary supplementation in female sexual function. A composition of Example 3 was given to thirty-nine (39) participants, ages 22-61 years. All individuals were experiencing some degree of sexual dysfunction. Evaluations were conducted using the Female Sexual Function Index (FSFI), a validated instrument used for the evaluation of sildenafil (Viagra) in women. Of the 39 participants, sixteen (16) received the composition and twenty-three (23) received placebo. At week four, 62.5% of women in the active group experienced improvement in clitoral sensation during sexual stimulation compared to 39.1% in the placebo group. In the active group, 68.8% experienced improvement in their level of sexual desire compared to 43.5% in the placebo group p=0.06. No headache, nausea, vomiting, stomach upset, visual disturbance, hypotension, dizziness or other complaints were noted in either group.
- All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.
Claims (46)
1. A composition for improving sexual fitness in an animal, which composition comprises L-arginine and a material for increasing nitric oxide synthase activity.
2. The composition of claim 1 , wherein said material for increasing nitric oxide synthase activity is ginseng.
3. The composition of claim 1 , further comprising a material to promote vascular circulation.
4. The composition of claim 3 , wherein the material for increasing nitric oxide synthase activity is ginseng and the material to promote vascular circulation is ginkgo biloba.
5. The composition of claim 4 , wherein said composition is a dietary supplement.
6. The composition of claim 5 , wherein said animal is a human.
7. The composition of claim 6 , wherein said human is a woman.
8. The composition of claim 7 , further comprising damiana.
9. The composition of claim 7 , comprising
(a) about 200 mg to about 600 mg L-arginine.
(b) about 10 mg to about 25 mg ginseng, and
(c) about 5 mg to about 15 mg ginkgo biloba.
10. The composition of claim 9 , further comprising about 5 mg to about 15 mg damiana.
11. The composition of claim 9 , wherein said ginseng is Korean ginseng.
12. The composition of claim 9 , further comprising in a unit dosage an amount of antioxidant vitamins, vitamin B complex, and minerals sufficient to provide up to 100% of the percent daily values of the antioxidant vitamins, vitamin B complex, and minerals upon administering an appropriate quantity of the unit dosages to achieve a desired daily dosage.
13. The composition of claim 9 , comprising
(a) about 300 mg to about 500 mg L-arginine,
(b) about 15 mg to about 20 mg ginseng, and
(c) about 5 mg to about 10 mg ginkgo biloba.
14. The composition of claim 7 , wherein said unit dosage is a capsule or a tablet.
15. The composition of claim 7 , wherein the unit dosage is an aqueous composition.
16. A method for improving sexual function in an animal, which method comprises administering a composition that comprises L-arginine and a material for increasing nitric oxide synthase activity.
17. The method of claim 16 , wherein said material for increasing nitric oxide synthase activity is ginseng.
18. The method of claim 16 , wherein said composition further comprises a material to promote vascular circulation.
19. The method of claim 18 , wherein said material for increasing nitric oxide synthase activity is ginseng and the material to promote vascular circulation is ginkgo biloba.
20. The method of claim 19 , wherein said composition is a dietary supplement.
21. The method of claim 20 , wherein said animal is a human.
22. The method of claim 21 , wherein said human is a woman.
23. The method of claim 22 , wherein the dietary supplement further comprises damiana.
24. The method of claim 22 , wherein the ginseng is Korean ginseng.
25. The method of claim 22 , wherein the unit dosage comprises
(a) about 200 mg to about 600 mg L-arginine,
(b) about 10 mg to about 25 mg ginseng,
(c) about 5 mg to about 10 mg ginkgo biloba, and
(d) about 5 mg to about 10 mg damiana.
26. The method of claim 25 , wherein the desired daily dosage of the dietary supplement comprises up to 100% of the percent daily values of antioxidant vitamins, vitamin B complex, and minerals.
27. The method of claim 25 , wherein the unit dosage comprises
(a) about 300 mg to about 500 mg L-arginine,
(b) about 15 mg to about 20 mg ginseng, and
(c) about 5 mg to about 10 mg ginkgo biloba.
28. The method of claim 22 , wherein the desired daily dosage of the dietary supplement comprises
(a) about 2500 mg L-arginine;
(b) about 100 mg Korean ginseng;
(c) about 50 mg ginkgo biloba;
(d) about 50 mg damiana;
(e) about 100% of the daily value of each of vitamins A, C, and E;
(f) about 100% of the daily value of each of thiamin, riboflavin, niacin, vitamin B-6, folate, vitamin B-12, biotin, and pantothenic acid; and
(g) about 50% of the daily value of each of calcium, iron, and zinc.
29. The method of claim 22 , wherein the dietary supplement is unit dosage in the form of a capsule or a tablet.
30. The method of claim 22 , wherein the dietary supplement is administered to the subject daily for at least two weeks.
31. The method of claim 22 , wherein the dietary supplement is administered daily to a female subject for a time sufficient to reduce discomfort during sexual intercourse.
32. The method of claim 22 , wherein the dietary supplement is administered daily to a female subject for a time sufficient to reduce dryness during sexual intercourse.
33. The method of claim 22 , wherein the dietary supplement is administered daily to a female subject for a time sufficient to improve clitoral sensation during sexual stimulation.
34. The method of claim 22 , wherein the combination is administered daily to a female subject for a time sufficient to improve the level of sexual desire.
35. The method of claim 22 , wherein the dietary supplement is administered daily to a female subject for a time sufficient to improve satisfaction with overall sex life.
36. The method of claim 22 , wherein the dietary supplement is administered daily to a female subject for a time sufficient to improve the quality of orgasm for the subject.
37. The method of claim 22 , wherein the dietary supplement is administered to a female subject for a period of time sufficient to improve the sexual fitness of the subject.
38. A method of treating sexual dysfunction in a female subject, comprising administering a sufficient quantity of unit dosages of a dietary supplement to achieve a desired daily dosage, the unit dosage comprising
(a) about 200 mg to about 600 mg L-arginine,
(b) about 10 mg to about 25 mg ginseng, and
(c) about 5 mg to about 10 mg ginkgo biloba
39. A method for preparing a composition useful for improving sexual function in an animal, which method comprises combining L-arginine with a material for increasing nitric oxide synthase activity.
40. The method of claim 39 , wherein said method further comprises combining a material to promote vascular circulation with L-arginine and the material for increasing nitric oxide synthase activity.
41. The method of claim 40 , wherein the material for increasing nitric oxide synthase activity is ginseng and the material to promote vascular circulation is ginkgo biloba.
42. The method of claim 39 , wherein the animal is a human.
43. An article of manufacture that comprises
(a) a composition of L-arginine and a material for increasing nitric oxide synthase activity, and
(b) labelling instructions for administering the composition to an animal over time at a rate sufficient to improve sexual function in the animal.
44. The article of manufacture of claim 43 , wherein (a) further comprises a material to promote vascular circulation.
45. The article of manufacture of claim 44 , wherein the material for increasing nitric oxide synthase activity is ginseng and the material to promote vascular circulation is ginkgo biloba.
46. The article of manufacture of claim 43 , wherein the animal is a human.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/407,221 US20030203053A1 (en) | 1998-04-03 | 2003-04-07 | Method and composition for improving sexual fitness |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8000998P | 1998-04-03 | 1998-04-03 | |
US9316498P | 1998-07-17 | 1998-07-17 | |
PCT/US1999/007427 WO1999051252A1 (en) | 1998-04-03 | 1999-04-02 | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
US09/410,446 US6368640B1 (en) | 1998-04-03 | 1999-10-01 | Method and composition for improving sexual fitness |
US10/117,171 US6544563B2 (en) | 1998-04-03 | 2002-04-08 | Method and composition for improving sexual fitness |
US10/407,221 US20030203053A1 (en) | 1998-04-03 | 2003-04-07 | Method and composition for improving sexual fitness |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/117,171 Division US6544563B2 (en) | 1998-04-03 | 2002-04-08 | Method and composition for improving sexual fitness |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030203053A1 true US20030203053A1 (en) | 2003-10-30 |
Family
ID=26762736
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/410,446 Expired - Lifetime US6368640B1 (en) | 1998-04-03 | 1999-10-01 | Method and composition for improving sexual fitness |
US10/097,423 Expired - Lifetime US7229649B2 (en) | 1998-04-03 | 2002-03-15 | Method and composition for improving sexual fitness |
US10/117,171 Expired - Lifetime US6544563B2 (en) | 1998-04-03 | 2002-04-08 | Method and composition for improving sexual fitness |
US10/407,221 Abandoned US20030203053A1 (en) | 1998-04-03 | 2003-04-07 | Method and composition for improving sexual fitness |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/410,446 Expired - Lifetime US6368640B1 (en) | 1998-04-03 | 1999-10-01 | Method and composition for improving sexual fitness |
US10/097,423 Expired - Lifetime US7229649B2 (en) | 1998-04-03 | 2002-03-15 | Method and composition for improving sexual fitness |
US10/117,171 Expired - Lifetime US6544563B2 (en) | 1998-04-03 | 2002-04-08 | Method and composition for improving sexual fitness |
Country Status (3)
Country | Link |
---|---|
US (4) | US6368640B1 (en) |
AU (1) | AU3221599A (en) |
WO (1) | WO1999051252A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005039320A2 (en) * | 2003-10-01 | 2005-05-06 | Boehringer Ingelheim International Gmbh | Composition for the activation of the immune system |
EP1570751A1 (en) * | 2004-03-02 | 2005-09-07 | Boehringer Ingelheim International GmbH | Composition for the activation of the immune system |
WO2006021930A2 (en) * | 2004-08-25 | 2006-03-02 | Femi-X A/S | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp |
US20060110478A1 (en) * | 2004-11-22 | 2006-05-25 | Mccleary Edward L | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
WO2011130608A1 (en) * | 2010-04-15 | 2011-10-20 | Life Science Enhancement Corporation | Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050196470A9 (en) * | 1998-04-03 | 2005-09-08 | Wuh Hank C | Method and composition for enhancing sexual desire |
US6905707B2 (en) * | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
WO2000012110A2 (en) * | 1998-08-26 | 2000-03-09 | Queen's University At Kingston | Use of anti(w)pressor agents for vascular remodeling in genital dysfunction |
US6548087B1 (en) * | 1999-07-12 | 2003-04-15 | Frances B. Kent | Nutritional supplement |
IL132460A0 (en) * | 1999-10-19 | 2001-03-19 | Laniado Shlomo | Sildenafil preparation |
US6476037B1 (en) * | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
US20040137081A1 (en) * | 2003-01-13 | 2004-07-15 | Peter Rohdewald | Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins |
WO2001092289A1 (en) * | 2000-05-31 | 2001-12-06 | Japan Science And Technology Corporation | SKIN TISSUE REGENERATION PROMOTERS COMPRISING GINSENOSIDE Rb1 |
PT1163904E (en) * | 2000-06-16 | 2006-07-31 | Rath Matthias | COMPOSITION FOR THE PREVENTION OF SMOOTH MUSCLE DISEASES, COMPOSING ASCORBATE, ARGININE AND MAGNESIUM |
US7128930B1 (en) | 2000-09-01 | 2006-10-31 | Meir S. Sacks | Compositions and methods for treating sexual dysfunction |
US6552074B2 (en) * | 2000-11-16 | 2003-04-22 | Fukumi Morishige | Arginine/ascorbic acid mixed powder as an oral supplement |
US6497885B2 (en) * | 2000-12-22 | 2002-12-24 | The Daily Wellness Company | Method and composition for improving fertility health in female and male animals and humans |
KR100488511B1 (en) * | 2002-05-09 | 2005-05-11 | 에스티케이제약 주식회사 | Health supplement including nature medicine ingredients and the composition thereof. |
US7214390B2 (en) * | 2003-02-07 | 2007-05-08 | Barmensen Labs, Llc | Topical compositions for enhancing sexual responsiveness |
EP1520584A1 (en) * | 2003-10-01 | 2005-04-06 | Boehringer Ingelheim International GmbH | Composition for the activation of the immune system |
CA2592631A1 (en) * | 2003-12-29 | 2005-07-21 | Jason Mcdevitt | Compositions and methods to treat recurrent medical conditions |
DE102004041270A1 (en) * | 2004-08-26 | 2006-03-02 | Merz Pharma Gmbh & Co. Kgaa | A capillary action system containing application differential differentiation compositions and their use |
US20060083724A1 (en) * | 2004-10-01 | 2006-04-20 | Hilst Todd W | Compositions for the treatment of femal sexual dysfunction |
US8231913B2 (en) * | 2005-11-10 | 2012-07-31 | Jose Angel Olalde Rangel | Angina pectoris and ischemic heart disease and synergistic phytoceutical composition for same |
US7303772B2 (en) * | 2005-11-10 | 2007-12-04 | Olalde Rangel Jose Angel | Synergistic phytoceutical compositions |
US7641440B2 (en) * | 2006-08-31 | 2010-01-05 | Siemens Energy, Inc. | Cooling arrangement for CMC components with thermally conductive layer |
WO2008125231A1 (en) * | 2007-04-17 | 2008-10-23 | Bayer Consumer Care Ag | Ginsenosides and extracts containing them combined with dexpanthenol |
AU2009216012A1 (en) * | 2008-02-19 | 2009-08-27 | Unigen, Inc. | Leaves extract of panax SP., a process of making the same and uses thereof |
FR2936953B1 (en) * | 2008-10-09 | 2012-09-21 | Holymark | ORAL COMPOSITION, ESPECIALLY FOOD SUPPLEMENT COMPRISING L-ARGININE AND DRY EXTRACTS OF MACE ROOTS AND DAMIANA LEAVES |
JP2010163425A (en) * | 2008-12-18 | 2010-07-29 | Daiichi Sankyo Healthcare Co Ltd | Medicinal composition containing phosphodiesterase-5 inhibitor and pantethine |
US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
CN104872751A (en) * | 2015-05-04 | 2015-09-02 | 威海御膳坊生物科技有限公司 | Anti-fatigue functional beverage and preparation method thereof |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
US11426439B2 (en) | 2018-03-20 | 2022-08-30 | Prophase Labs, Inc. | Nutritional product and method of using it |
US20220117284A1 (en) * | 2020-09-28 | 2022-04-21 | Cytosolve, Inc. | Compositions for Improving Low Testosterone Levels |
Citations (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2878124A (en) * | 1956-03-10 | 1959-03-17 | Bayer Ag | Food additives |
US3015567A (en) * | 1959-03-20 | 1962-01-02 | Du Pont | Process for enriching the l-lysine content of food and the resulting product |
US3360374A (en) * | 1965-07-27 | 1967-12-26 | Courtland Lab | Process for making a dietary food product |
US3970750A (en) * | 1974-10-08 | 1976-07-20 | Sandoz, Inc. | Effervescent potassium chloride composition |
US4000276A (en) * | 1972-09-29 | 1976-12-28 | Kanebo, Ltd. | Cosmetic composition containing vitamin e orotate |
US4154813A (en) * | 1976-06-18 | 1979-05-15 | Israel Kleinberg | Means and method for improving natural defenses against caries |
US4168307A (en) * | 1974-11-08 | 1979-09-18 | Mitsubishi Chemical Industries Limited | N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof |
US4340592A (en) * | 1980-03-14 | 1982-07-20 | Adibi Siamak A | Nutrient compositions and method of administering the same |
US4388325A (en) * | 1980-06-30 | 1983-06-14 | Societa' Italo-Britannica L. Manetti-H. Roberts & C. | L-Arginine D,L-pyroglutamate as a pharmaceutical agent having an activity at the neuro-endocrinal level |
US4599232A (en) * | 1983-02-16 | 1986-07-08 | Sigma Tau Industrie Faramaceutiche Riunite S.P.A. | Pharmaceutical composition with metabolic and energetic activity for the use in cardiac and vascular therapy |
US4900566A (en) * | 1986-02-08 | 1990-02-13 | The Howard Foundation | Confectionary product and a process for producing the same |
US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
US4957938A (en) * | 1989-06-21 | 1990-09-18 | Abbott Laboratories | Nutritional formulation for the treatment of renal disease |
US5032608A (en) * | 1986-09-10 | 1991-07-16 | Dudrick Stanley J | Method and substrate composition for treating atherosclerosis |
US5034377A (en) * | 1984-11-19 | 1991-07-23 | Montefiore Hospital Association Of Western Pennsylvania | Aqueous nutrient compositions comprising oligopeptides |
US5036052A (en) * | 1988-06-22 | 1991-07-30 | Morishita Pharmaceutical Co., Ltd. | Amino acid nutrient compositions |
US5041429A (en) * | 1988-06-01 | 1991-08-20 | Sanwa Kagaku Kenkyusho Co., Ltd. | Cell activators, circulatory ameliorators and edible compositions |
US5106836A (en) * | 1991-02-22 | 1992-04-21 | Clintec Nutrition Co. | Enteral diet |
US5157022A (en) * | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
US5171217A (en) * | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5221668A (en) * | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
US5248688A (en) * | 1986-09-10 | 1993-09-28 | Dudrick Medical Research Fund I, Ltd. | Method and substrate composition for treating atherosclerosis |
US5262435A (en) * | 1992-02-10 | 1993-11-16 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5278189A (en) * | 1990-06-04 | 1994-01-11 | Rath Matthias W | Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A) |
US5288490A (en) * | 1989-05-24 | 1994-02-22 | Temple University Of The Commonwealth System Of Higher Education | Thrombus-targeted complexes of plasminogen activator and fibrin fragments |
US5296246A (en) * | 1991-08-08 | 1994-03-22 | Fujix Corporation | Active amino acid Ca, beverages containing same, and process for their production |
US5328569A (en) * | 1992-06-26 | 1994-07-12 | Beloit Technologies, Inc. | Curved suction box apparatus in a papermaking machine press section |
US5334617A (en) * | 1984-03-19 | 1994-08-02 | The Rockefeller University | Amino acids useful as inhibitors of the advanced glycosylation of proteins |
US5364644A (en) * | 1990-05-16 | 1994-11-15 | Board Of Regents, The University Of Texas System | Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders |
US5374651A (en) * | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
US5380945A (en) * | 1989-06-21 | 1995-01-10 | Abbott Laboratories | Guanidino compounds as regulators of nitric oxide synthase |
US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
US5411956A (en) * | 1989-12-25 | 1995-05-02 | Nisshin Flour Milling Co., Ltd. | Lipolytic enzyme inhibitors |
US5428070A (en) * | 1993-06-11 | 1995-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity |
US5439938A (en) * | 1993-04-07 | 1995-08-08 | The Johns Hopkins University | Treatments for male sexual dysfunction |
US5464644A (en) * | 1989-09-27 | 1995-11-07 | Kellogg Company | Ready-to-eat-cereal containing psyllium and use thereof for lowering cholesterol levels |
US5500226A (en) * | 1993-06-21 | 1996-03-19 | Zambon Group S.P.A. | Pharmaceutical composition having analgesic activity |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5545276A (en) * | 1994-03-03 | 1996-08-13 | Milliken Research Corporation | Process for forming cushion backed carpet |
US5576351A (en) * | 1989-12-29 | 1996-11-19 | Mcgaw, Inc. | Use of arginine as an immunostimulator |
US5594032A (en) * | 1994-11-10 | 1997-01-14 | Gonzalez-Cadavid; Nestor F. | Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA |
US5626883A (en) * | 1994-04-15 | 1997-05-06 | Metagenics, Inc. | Ascorbic acid compositions providing enhanced human immune system activity |
US5631031A (en) * | 1994-06-13 | 1997-05-20 | Meade; Thomas L. | Water-insoluble amino acid salt |
US5650418A (en) * | 1990-06-04 | 1997-07-22 | Therapy 2000 | Therapeutic lysine salt composition and method of use |
US5730987A (en) * | 1996-06-10 | 1998-03-24 | Omar; Lotfy Ismail | Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba |
US5776460A (en) * | 1995-06-07 | 1998-07-07 | Man Ki Park | Processed ginseng product with enhanced pharmacological effects |
US5780039A (en) * | 1992-04-23 | 1998-07-14 | Novartis Nutrition Ag | Orally-ingestible nutrition compositions having improved palatability |
US5852058A (en) * | 1993-06-11 | 1998-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US5861168A (en) * | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5897864A (en) * | 1996-05-23 | 1999-04-27 | Cohen; Alan J. | Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba |
US5945452A (en) * | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
US6117872A (en) * | 1998-06-23 | 2000-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity |
US6156802A (en) * | 1997-05-27 | 2000-12-05 | Kaneka Corporation | Cholesterol-lowering composition |
US6242012B1 (en) * | 1999-10-19 | 2001-06-05 | Thomas Newmark | Herbal composition for promoting hormonal balance in women and methods of using same |
US6323211B1 (en) * | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
US6338882B1 (en) * | 1999-03-23 | 2002-01-15 | Deutsche Telekom Ag | Process for applying a light-blocking layer between a photoconducting layer and a mirror when manufacturing an optically addressable spatial light modulator |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0511587A1 (en) | 1991-04-26 | 1992-11-04 | Takeda Chemical Industries, Ltd. | Slimming composition |
AT397224B (en) * | 1991-05-14 | 1994-02-25 | Wolf Systembau Gmbh & Co Kg | METHOD AND DEVICE FOR PRODUCING SQUARE EDGE FROM TREE TRUNKS OD. DGL. |
JPH05163139A (en) | 1991-12-12 | 1993-06-29 | Ajinomoto Co Inc | Antiarteriosclerotic agent |
JPH05163193A (en) | 1991-12-18 | 1993-06-29 | Showa Kako Kk | Separation of tartaric acid |
WO1993018156A1 (en) | 1992-03-05 | 1993-09-16 | The General Hospital Corporation | Endothelial nitric oxide synthase |
GB9214247D0 (en) * | 1992-07-04 | 1992-08-19 | Stephan Peter M | Composition for use as a food or food supplement |
US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
JPH06321786A (en) | 1993-05-12 | 1994-11-22 | Sekisui Chem Co Ltd | Agent for inhibiting absorption of bile acid in enteric canal |
ZA9410015B (en) | 1993-09-15 | 1995-11-08 | William Henry Davis | A pharmaceutical composition |
US5576287A (en) | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
CN1107349A (en) * | 1994-10-10 | 1995-08-30 | 万县市制药厂 | Ginkgo preparation for treatment of heart disease |
US5523087A (en) * | 1995-02-15 | 1996-06-04 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction |
US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
-
1999
- 1999-04-02 WO PCT/US1999/007427 patent/WO1999051252A1/en active Application Filing
- 1999-04-02 AU AU32215/99A patent/AU3221599A/en not_active Abandoned
- 1999-10-01 US US09/410,446 patent/US6368640B1/en not_active Expired - Lifetime
-
2002
- 2002-03-15 US US10/097,423 patent/US7229649B2/en not_active Expired - Lifetime
- 2002-04-08 US US10/117,171 patent/US6544563B2/en not_active Expired - Lifetime
-
2003
- 2003-04-07 US US10/407,221 patent/US20030203053A1/en not_active Abandoned
Patent Citations (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2878124A (en) * | 1956-03-10 | 1959-03-17 | Bayer Ag | Food additives |
US3015567A (en) * | 1959-03-20 | 1962-01-02 | Du Pont | Process for enriching the l-lysine content of food and the resulting product |
US3360374A (en) * | 1965-07-27 | 1967-12-26 | Courtland Lab | Process for making a dietary food product |
US4000276A (en) * | 1972-09-29 | 1976-12-28 | Kanebo, Ltd. | Cosmetic composition containing vitamin e orotate |
US3970750A (en) * | 1974-10-08 | 1976-07-20 | Sandoz, Inc. | Effervescent potassium chloride composition |
US4168307A (en) * | 1974-11-08 | 1979-09-18 | Mitsubishi Chemical Industries Limited | N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof |
US4154813A (en) * | 1976-06-18 | 1979-05-15 | Israel Kleinberg | Means and method for improving natural defenses against caries |
US4340592A (en) * | 1980-03-14 | 1982-07-20 | Adibi Siamak A | Nutrient compositions and method of administering the same |
US4388325A (en) * | 1980-06-30 | 1983-06-14 | Societa' Italo-Britannica L. Manetti-H. Roberts & C. | L-Arginine D,L-pyroglutamate as a pharmaceutical agent having an activity at the neuro-endocrinal level |
US4599232A (en) * | 1983-02-16 | 1986-07-08 | Sigma Tau Industrie Faramaceutiche Riunite S.P.A. | Pharmaceutical composition with metabolic and energetic activity for the use in cardiac and vascular therapy |
US5334617A (en) * | 1984-03-19 | 1994-08-02 | The Rockefeller University | Amino acids useful as inhibitors of the advanced glycosylation of proteins |
US5034377A (en) * | 1984-11-19 | 1991-07-23 | Montefiore Hospital Association Of Western Pennsylvania | Aqueous nutrient compositions comprising oligopeptides |
US4900566A (en) * | 1986-02-08 | 1990-02-13 | The Howard Foundation | Confectionary product and a process for producing the same |
US5248688A (en) * | 1986-09-10 | 1993-09-28 | Dudrick Medical Research Fund I, Ltd. | Method and substrate composition for treating atherosclerosis |
US5032608A (en) * | 1986-09-10 | 1991-07-16 | Dudrick Stanley J | Method and substrate composition for treating atherosclerosis |
US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
US5041429A (en) * | 1988-06-01 | 1991-08-20 | Sanwa Kagaku Kenkyusho Co., Ltd. | Cell activators, circulatory ameliorators and edible compositions |
US5036052A (en) * | 1988-06-22 | 1991-07-30 | Morishita Pharmaceutical Co., Ltd. | Amino acid nutrient compositions |
US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
US5288490A (en) * | 1989-05-24 | 1994-02-22 | Temple University Of The Commonwealth System Of Higher Education | Thrombus-targeted complexes of plasminogen activator and fibrin fragments |
US5380945A (en) * | 1989-06-21 | 1995-01-10 | Abbott Laboratories | Guanidino compounds as regulators of nitric oxide synthase |
US4957938A (en) * | 1989-06-21 | 1990-09-18 | Abbott Laboratories | Nutritional formulation for the treatment of renal disease |
US5464644A (en) * | 1989-09-27 | 1995-11-07 | Kellogg Company | Ready-to-eat-cereal containing psyllium and use thereof for lowering cholesterol levels |
US5157022A (en) * | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
US5411956A (en) * | 1989-12-25 | 1995-05-02 | Nisshin Flour Milling Co., Ltd. | Lipolytic enzyme inhibitors |
US5576351A (en) * | 1989-12-29 | 1996-11-19 | Mcgaw, Inc. | Use of arginine as an immunostimulator |
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5364644A (en) * | 1990-05-16 | 1994-11-15 | Board Of Regents, The University Of Texas System | Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders |
US5278189A (en) * | 1990-06-04 | 1994-01-11 | Rath Matthias W | Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A) |
US5650418A (en) * | 1990-06-04 | 1997-07-22 | Therapy 2000 | Therapeutic lysine salt composition and method of use |
US5106836A (en) * | 1991-02-22 | 1992-04-21 | Clintec Nutrition Co. | Enteral diet |
US5171217A (en) * | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
US5296246A (en) * | 1991-08-08 | 1994-03-22 | Fujix Corporation | Active amino acid Ca, beverages containing same, and process for their production |
US5374651A (en) * | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
US5262435A (en) * | 1992-02-10 | 1993-11-16 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5221668A (en) * | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
US5780039A (en) * | 1992-04-23 | 1998-07-14 | Novartis Nutrition Ag | Orally-ingestible nutrition compositions having improved palatability |
US5328569A (en) * | 1992-06-26 | 1994-07-12 | Beloit Technologies, Inc. | Curved suction box apparatus in a papermaking machine press section |
US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
US5439938A (en) * | 1993-04-07 | 1995-08-08 | The Johns Hopkins University | Treatments for male sexual dysfunction |
US5861168A (en) * | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US5945452A (en) * | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
US5428070A (en) * | 1993-06-11 | 1995-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5852058A (en) * | 1993-06-11 | 1998-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US5500226A (en) * | 1993-06-21 | 1996-03-19 | Zambon Group S.P.A. | Pharmaceutical composition having analgesic activity |
US5545276A (en) * | 1994-03-03 | 1996-08-13 | Milliken Research Corporation | Process for forming cushion backed carpet |
US5626883A (en) * | 1994-04-15 | 1997-05-06 | Metagenics, Inc. | Ascorbic acid compositions providing enhanced human immune system activity |
US5631031A (en) * | 1994-06-13 | 1997-05-20 | Meade; Thomas L. | Water-insoluble amino acid salt |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5767160A (en) * | 1994-10-05 | 1998-06-16 | Notol, Inc. | Method and formulation of stimulating nitric oxide synthesis |
US5594032A (en) * | 1994-11-10 | 1997-01-14 | Gonzalez-Cadavid; Nestor F. | Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA |
US5776460A (en) * | 1995-06-07 | 1998-07-07 | Man Ki Park | Processed ginseng product with enhanced pharmacological effects |
US6323211B1 (en) * | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
US5897864A (en) * | 1996-05-23 | 1999-04-27 | Cohen; Alan J. | Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba |
US5730987A (en) * | 1996-06-10 | 1998-03-24 | Omar; Lotfy Ismail | Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba |
US6156802A (en) * | 1997-05-27 | 2000-12-05 | Kaneka Corporation | Cholesterol-lowering composition |
US6117872A (en) * | 1998-06-23 | 2000-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity |
US6338882B1 (en) * | 1999-03-23 | 2002-01-15 | Deutsche Telekom Ag | Process for applying a light-blocking layer between a photoconducting layer and a mirror when manufacturing an optically addressable spatial light modulator |
US6242012B1 (en) * | 1999-10-19 | 2001-06-05 | Thomas Newmark | Herbal composition for promoting hormonal balance in women and methods of using same |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007507441A (en) * | 2003-10-01 | 2007-03-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Immune system activation composition |
WO2005039320A3 (en) * | 2003-10-01 | 2005-07-14 | Boehringer Ingelheim Int | Composition for the activation of the immune system |
WO2005039320A2 (en) * | 2003-10-01 | 2005-05-06 | Boehringer Ingelheim International Gmbh | Composition for the activation of the immune system |
EP1570751A1 (en) * | 2004-03-02 | 2005-09-07 | Boehringer Ingelheim International GmbH | Composition for the activation of the immune system |
WO2006021930A2 (en) * | 2004-08-25 | 2006-03-02 | Femi-X A/S | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp |
WO2006021930A3 (en) * | 2004-08-25 | 2006-05-26 | Femi X As | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp |
US20060110478A1 (en) * | 2004-11-22 | 2006-05-25 | Mccleary Edward L | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8197854B2 (en) | 2005-08-04 | 2012-06-12 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263667B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
WO2011130608A1 (en) * | 2010-04-15 | 2011-10-20 | Life Science Enhancement Corporation | Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction |
US20130210867A1 (en) * | 2010-04-15 | 2013-08-15 | Life Science Enhancement Corporation | Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction |
Also Published As
Publication number | Publication date |
---|---|
US7229649B2 (en) | 2007-06-12 |
US6368640B1 (en) | 2002-04-09 |
AU3221599A (en) | 1999-10-25 |
US20020146471A1 (en) | 2002-10-10 |
US6544563B2 (en) | 2003-04-08 |
US20020155181A1 (en) | 2002-10-24 |
WO1999051252A1 (en) | 1999-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6368640B1 (en) | Method and composition for improving sexual fitness | |
AU2002310212B2 (en) | Method and composition for enhancing sexual desire | |
CN101460159B (en) | Fatigue-reducing agent | |
CN102438642A (en) | Composition comprising green tea extract | |
CA2518658A1 (en) | Composition and method for appetite and craving suppression and mood enhancement | |
AU2002310212A1 (en) | Method and composition for enhancing sexual desire | |
KR20050047130A (en) | Composition comprising panax ginseng and paullinia cupana extracts | |
US20200022949A1 (en) | Composition and method for the alleviation of effects of alcohol consumption | |
KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
WO2012067745A1 (en) | Compositions and methods for treating erectile dysfunction | |
US20060110478A1 (en) | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction | |
US7371415B1 (en) | Method and composition for improving sexual fitness | |
KR20100129571A (en) | Functional composition for improvement of sex and food having the same | |
JP5602696B2 (en) | Improvement of sexual function and genital vasculature by proanthocyanidins | |
US20060269623A1 (en) | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men | |
KR102180363B1 (en) | An anti-impotence formula comprising black sesame and yeast hydrolysate | |
CA2446254C (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits | |
US20060110477A1 (en) | Composition and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction | |
RU2722728C1 (en) | Kit for appetite control and body weight normalization and method of its application | |
JP4435882B2 (en) | Alcohol absorption inhibiting composition | |
US20240307476A1 (en) | Powdered food supplement for producing a beverage | |
US20050266096A1 (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits | |
KR20030087761A (en) | healthy cadence foodstuffs and that composion for increaing male vitality | |
US20220000953A1 (en) | Antihypertensive Composition | |
Amagase | A combination of various functional food ingredients as a weight management program: randomized, placebo-controlled, and double-blind human clinical studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |